Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ratain, M. J.
Right arrow Articles by Daly, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ratain, M. J.
Right arrow Articles by Daly, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Treatment of hairy cell leukemia with recombinant alpha 2 interferon

MJ Ratain, HM Golomb, JW Vardiman, EE Vokes, RH Jacobs and K Daly

Nine patients with progressive hairy cell leukemia were treated with subcutaneous injections of recombinant alpha 2 interferon (2 to 10 X 10(6) U/m2) three times weekly. Eight patients completed at least eight weeks of treatment and were evaluable; one patient with refractory thrombocytopenia died of an intracerebral hemorrhage after two doses of interferon. Seven of eight patients responded, with responses occurring as early as two weeks. Four patients also had resolution of their monocytopenia. No complete responses were seen with up to 30 weeks of treatment. Bone marrow biopsies demonstrated improvement in all eight patients. No unforeseen toxicity occurred, but most patients had transient myelosuppression during the first few weeks of treatment. Recombinant alpha 2 interferon is effective in the treatment of hairy cell leukemia, with acceptable toxicity.

Volume 65, Issue 3, pp. 644-648, 03/01/1985
Copyright © 1985 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
F. Ravandi, J. L. Jorgensen, S. M. O'Brien, S. Verstovsek, C. A. Koller, S. Faderl, F. J. Giles, A. Ferrajoli, W. G. Wierda, S. Odinga, et al.
Eradication of minimal residual disease in hairy cell leukemia
Blood, June 15, 2006; 107(12): 4658 - 4662.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. A. Thomas, S. O'Brien, C. Bueso-Ramos, S. Faderl, M. J. Keating, F. J. Giles, J. Cortes, and H. M. Kantarjian
Rituximab in relapsed or refractory hairy cell leukemia
Blood, December 1, 2003; 102(12): 3906 - 3911.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. L. FAHEY, G. SARNA, R. P. GALE, and R. SEEGER
Immune Interventions in Disease
Ann Intern Med, February 1, 1987; 106(2): 257 - 274.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
R. CHAMPLIN, R. P. GALE, K. A. FOON, and D. W. GOLDE
Chronic Leukemias: Oncogenes, Chromosomes, and Advances in Therapy
Ann Intern Med, May 1, 1986; 104(5): 671 - 688.
[Abstract] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1985 by American Society of Hematology         Online ISSN: 1528-0020